Introduction: Cutaneous graft-versus-host disease (GVHD) is an antigen presenting cell mediated process which leads donor T lymphocytes to presumably target keratinocyte progenitor cells at the dermal-epidermal junction. In the absence of inflammation, epidermal dendritic cells (a.k.a. Langerhans cells or LCs) can self-renew for long periods of time without the requirement for a bone-marrow derived blood-borne precursor. Murine models have suggested that depletion of host LCs pretransplant prevents cutaneous GVHD. We sought to determine epidermal dendritic cell density pre-transplant, post-transplant, and with the onset of acute GVHD. Methods: We reviewed all skin biopsies performed on 2101 stem cell transplants patients at Loyola University Medical Center from 1995-2005. From these paraffin-embedded blocks, 20 randomly selected acute GVHD biopsies, all 17 biopsies of non-GVHD rashes in post allograft patients, and 12 normal skin biopsies from reduction mammoplasties were obtained. In addition as part of a prospective trial, 14 patients underwent punch biopsies from December 2004 to August 2005 of grossly normal skin before and immediately following the completion of their conditioning regimens. All biopsies were stained for CD1a (LC marker) and the number of suprabasal stained cells per high power field (HPF) were counted by a dermatopathologist. Results: Total body irradiation containing (TBI) conditioning regimens nearly completely eliminated epidermal LCs by the day of transplant. In comparison to normal skin (44 CD1aϩ cells Ϯ 4.7 [95% CI]), acute GVHD lesions showed a depletion of epidermal LCs (3.7 CD1aϩ cells Ϯ 3.2 [95% CI]), but so did biopsies obtained post allograft without GVHD (6.5 CD1aϩ cells Ϯ 3.6 [95% CI]). Conclusions: Myeloablative conditioning regimens deplete epidermal LCs and this reduction may remain post engraftment. UV dermatitis, topical steroids or tacrolimus, viral infections (HPV, HIV), and GVHD all induce LC depletion. The mechanism for this depletion is unknown but mediators such as TNF-␣ and IL-1 have induced LC migration in murine models (Roake JE, J Exp Med, 1995) . Our data suggest that pretransplant LC depletion in humans will not prevent cutaneous GVHD. Future studies will need to be performed to determine the origin of LCs in post allograft patients. Skarica, M., Radojcic, V., Luznik, L. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD. We recently found in murine models that after MHC-matched allografting, the residual host LCs, the major dendritic cells (DCs) of the skin, survive in epidermis despite the presence of large numbers of peripheral donor T cells in the graft and conversion to the full donor DC chimerism in blood. This observation led us to hypothesize that in vivo manipulation of residual host LCs, which persist in complete donor chimeras after MHC-matched allografting, may have a central role in augmenting DLI-mediated alloimmune responses. We tested our hypothesis in two murine models of MHC-matched allografting. To manipulate T cell-LC interaction in vivo we used the Toll-like receptor 7 (TLR7) ligand imiquimod. Topical application of imiquimod is known to augment in situ maturation of the LCs and enhance their emigration from the skin to the skin-draining lymph nodes (LNs). We first tracked the in vivo fate of DLI-derived T cells after their administration to the 8-week-old B6.SJL3 C3H.SW complete donor chimeras that were pretreated with vehicle or imiquimod. As DLI, we used purified donor T cells from the B6.PL-Thy1 a mice that differ in the expression of Thy 1.1 allele. In the imiquimod treated group, the expansion of DLI-derived Thy 1.1 ϩ T cells in LNs and spleen was significantly better than that of the vehicle-treated group. This augmented DLI-mediated GVH response was also reflected by a higher number of DLI-derived CD8 ϩ INF-␥ secreting T cells and by an increase in donor-derived LC chimerism in the imiquimodtreated group. Next, we tested the effect of imiquimod on the GVL reactivity of DLI. Four-week-old C3H.SW3 C57/BL6 chimeras constructed after lethal conditioning were pretreated with imiquimod prior to DLI administration and lethal challenge with C1498 leukemia cells. Chimeras that received imiquimod and DLI had superior leukemia-free survival in comparison to animals that received DLI plus vehicle (P Ͻ .01) or imiquimod alone (P Ͻ .02). The superior leukemia-free survival in the group that received DLI plus imiquimod correlated also with faster conversion to full donor CD8 ϩ T cell chimerism in comparison to the DLI plus vehicle group (P Ͻ .01). In both models, we have not observed any significant clinical signs of GVHD. These results indicate that imiquimod, through its action on LCs, can be used to enhance the DLI-mediated alloimmune responses including their GVL reactivity without exacerbating GVHD. It has been recognized that dysfunction of CB cellular immunity is in part due to the immaturity of the CB cellular immune system (Cairo, 1997) . However, biological pathways and molecular mechanisms associated with the immaturity of CB cellular immunity are still poorly understood. Recently we have utilized oligonucleotide microarray to examine gene expression profile of CB vs APB Mo and have demonstrated significant differential gene expression patterns (Jiang/Cairo, 2004 ). In the current study, differential expressed genes and proteins were examined in Mo-derived CB vs APB DC by means of oligonucleotide microarray and proteomics. Briefly, Mo were purified and cultured for 8 days with GM-CSF, IL-4 and LPS. Oligonucleotide microarray was carried out (Affymetrix). The proteomic study was conducted by liquid chromatography (LC) and tandem mass spectrometry (MS/MS). We identified gene expression patterns that were significantly lower in CB Poster Session I vs APB DC including surface molecules HLA-DQA1 (4F), HLA-DRB3 (5F); cytokine/chemokine genes IL6 (2.9F), IL12B (3.5F), CXCL10 (6.6F); immunoregulatory genes ISG20 (11F), TNFSF10 (4.5F). The proteomic results indicated several zinc finger proteins (292, 221) (2-5F) and interleukin-4 precursor (7.7F) were expressed higher in APB vs CB (mDC). In contrast, cell cycle regulators cyclin I (3F), Rb-like protein 2 (4.35 F) were significantly lower in APB vs CB DC. We then compared CB vs APB DC antigen presentation activity to APB CD8 T cells by ELISPOT assay for interferon-r (IFNr) production (BD Pharmingen). Briefly, CD8 T cells (MHC HLA A2) were incubated with CB or APB DC that were loaded without or with influenza peptide onto ELISPOT plate. Influenza peptide loaded CB mDC significantly reduced the ability to induce CD8 T cells to produce IFNr compared with APB mDC (3.5F). We postulate that decreased expression of specific surface molecules and other genes and proteins resulting in lower surface protein expression in CB DC may in part be responsible for the lack of initiation of cell surface signaling events to trigger CB-DC to induce activation of CD8 T cells. Furthermore, these significantly decreased expressed genes and proteins in LPS-CB vs APB DC may also partially be responsible for differential innate and adaptive immune function and properties of CB vs. APB. No in vivo models exist to consistently examine the impact of ex vivo manipulation of human T cells (huT) on T cell function. NOD SCID␤2M null mice (␤2) were conditioned with 250 cGy TBI on day Ϫ1 (n ϭ 34), or 300 cGy on day 0 (n ϭ 21). 10 7 naive or CD3/28 bead activated (Xcyte™ Dynabeads) huT (Act) were injected retro-orbitally (ro). Engraftment of huT was evaluated weekly by FACS and euthanasia was performed if mice lost Ͼ20% body weight. ␤2 mice receiving 250 or 300 cGy ϩ naive, or 300 cGy ϩ Act developed 60%, 75%, and 100% lethal GVHD respectively. The huT engraftment was 20 Ϯ 15%, 33 Ϯ 21%, and 59 Ϯ 19% respectively. Infiltration of murine tissues was greatest in mice receiving 300 cGy ϩ Act huT (spleen, liver, lung, kidney: Ϯ60%). Of interest, serum human IFN␥ levels increased over time in all mice who developed lethal GVHD (P Ͻ .05). Importantly, histological examination of the target tissues revealed changes consistent with human GVHD. We developed a chimeric suicide gene consisting of human CD34 and full length HSV-tk and showed that the fusion protein ⌬CD34-TK conferred ganciclovir (GCV) sensitivity and provided a surface marker for selection of transduced cells (Td). To generate Td cells we used CD3/28 beads ϩ IL-2, and after 2 days cells were incubated with 293 GPG-derived VSV-G pseudotyped CD34-tk oncoretroviral supernatants for 6h at 37C. Td cells were then expanded for 2 more days and isolated by MACS (Miltenyi Biotech) and purified to Ͼ99% by CD34 (VarioMACS). To evaluate the Td GVHD potential, ␤2 mice received 300 cGy and were injected with 10 7 Act (n ϭ 7) or Td (n ϭ 4) huT. Both groups developed similar engraftment with 49 Ϯ 23% and 49 Ϯ 10% huT respectively (P ϭ NS); had important infiltration in target organs (Ϯ55% in the liver), and developed lethal GVHD. Subsequently, we evaluated the ability of GCV (days 1-7) to prevent GVHD after infusion of Td. ␤2 mice (n ϭ 8) conditioned with 300 cGy were injected ro with 10 7 Td and 50% received GCV. We efficiently eliminated Td huT with GCV (day 3 0.1 Ϯ 0.06; day 24 0.1 Ϯ 0.1 Td cells). In summary, we developed a xenogeneic model of lethal GVHD where naive, ex vivo activated, or Td selected CD34tk huT injected ro into sublethally irradiated ␤2 mice engraft, expand in vivo, infiltrate target tissues sharing the major characteristics of human GvHD, and causing the death of mice. Interestingly, Td T cells could be efficiently eliminated in vivo by treatment with GCV, meaning we could potentially control human GVHD with the suicide system. Shimoni, A., Trakhtenbrot, L., Ishoev, G., Hardan, I., Shem-Tov, N., Rechavi, G., Amariglio, N., Nagler, A. Chaim Sheba Medical Center, Tel-Hashomer, Israel. Chimerism within cellular subsets following allogeneic SCT has been studied extensively, yet there is only limited data on chimerism kinetics within plasma cells (PC) and its prognostic significance. In this study we prospectively analyzed the relative ratios of recipient and donor-derived PC in pts with acute leukemia at serial time-points following SCT from a sex-mismatched donor in relation to SCT outcomes. Bone-marrow (BM) preparations were evaluated by a Duet combined cytogenetic/morphologic analysis system (Bioview LtD, Israel). The system scans BM preparations and saves all cell coordinates. PC are detected and marked by their morphology. The stain is then removed and FISH for ϫ and Y markers is applied to the same slide allowing differentiation of recipient and donor PC by their gender. The study included 50 pts following myeloablative (n ϭ 22) or reduced-intensity conditioning (n ϭ 28). Thirty-six pts (72%) had recipient PC detected early after SCT, constituting 0.01-1.6% of BM cells. This was often associated with low level recipient chimerism (Ͻ1%) in lymphocytes. Early detection of recipient PC was not related to donor type, conditioning regimen or acute GVHD, and had no prognostic significance. The median time to disappearance of recipient PC was 12 months. In 16 of the 36 pts with recipient PC they persisted beyond 6 months (and up to Ͼ18 months), in 10 they disappeared by this time period, 6 died before 6 months with recipient PC and 4 have insufficient follow-up. Persistence of recipient PC beyond 6 months was not associated with mixed-chimerism in other subsets at this stage. BM tests beyond 6 months are available in 30 pts of all 50 pts. The outcome of 16 pts with recipient PC persisting beyond 6 months was significantly inferior to 14 pts with no recipient PC at this stage; 8 patients in the first group relapsed compared to only 1 pt in the second. The 2-year DFS was 35% (7-62), and 91% (74-100), respectively (P ϭ .02). Donor derived PC were detected during the course in 27 pts. The estimated median time to first detection of donor PC was 6 months (1-15). Engraftment kinetics of donor PC had no relation to SCT outcomes. In conclusion, recipient PC may persist for long durations after allogeneic SCT and are relatively resistant to conditioning and to allogeneic responses. Persistence of recipient PC beyond 6 months is a surrogate marker for ineffective GVL, even in pts with GVHD, and is therefore associated with an increased risk for leukemia relapse. Diaz, M.A., Ramirez, M., Perez-Martinez, A., Gonzalez-Vicent, M., Garcia-Castro, J., Madero, L. Hematopoietic Stem Cell Transplantation Unit, Hospital "Niñ o Jesus," Madrid, Spain. To maximize graft-versus-leukemia (GvL) effect while minimizing transplant-related morbidity and mortality, we designed a study of allogeneic PBSC CD34ϩ selected transplantation followed by DLI. PBSC CD34ϩ selection was performed by CliniMACS device. Between June 2004 and July 2005, sixteen consecutive patients (4 females and 12 males) aged between 1-12 years (median 6 years) diagnosed with AML 6, ALL 10 were conditioned with fludarabine 30 mg/m 2 /day ϫ 4 days and melphalan 140 mg/m 2 /day ϫ 1 day. Status at transplantation was 1st CR 10, 2nd CR 5 and 3rd CR 1. GvHD prophylaxis consisted of
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